Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of subjects with and without new digital ulcer (DU) development during follow-up

From: Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis

Patient characteristics at baseline
n = 761
Patients with new DUs
(n = 22)
Patients without new DUs
(n = 54)
p value Odds ratio 95%CI; p value for cut-off
♀: n (%) 17 (77.3%) 45 (83.3%) ns   
Mean age in years (± SD) at
 -Enrollment 56 (± 12.9) 56 (± 15.0) ns   
 -Raynaud’s onset 43 (± 14.4) 42 (± 16.4) ns   
 -Onset of first non-Raynaud’s symptom 45 (± 14.7) 46 (± 15.2) ns   
Smoking
 -Current smokers, n (%) 5 (22.7%) 6 (11.1%) ns   
 -Mean pack years (± SD) 13.66 (± 16.38) 8.040 (± 13.4) ns   
dcSSc, n (%) 13 (59.1%) 14 (25.9%) 0.0087 4.1 1.5–11.7; p = 0.0087
Mean modified Rodnan skin score (± SD) 13.4 (± 9.4) 6.7 (± 6.9) 0.0008 9.43 3.0–29.2; p < 0.0001
ACR/EUSTAR score (± SD) 19.7 (± 4.0) 15.6 (± 4.1) 0.0004 8.14 2.5–25.6; p = 0.0003
 -Skin involvement
  -Thickening prox. of MCP, n (%) 12 (54.5%) 13 (24.1%)    
  -Sclerodactyly, n (%) 9 (40.9%) 33 (9.1%) 0.0308 3.85 1.3-10.8; p = 0.0154
  -Puffy fingers, n (%) 1 (4.5%) 6 (61.1%)    
  -Sine scleroderma 0 2 (3.7%)    
 -Digital tip ulcers, n (%) 16 (72.7%) 20 (37.0%) 0.0058 4.5 1.5–13.5
 -Pitting scars, n (%) 18 (81.8%) 22 (40.7%) 0.0020 6.5 1.9–22.0
 -Teleangiectesia, n (%) 17 (77.3%) 43 (79.6%) ns   
 -Abnormal capillaroscopy, n (%) 22 (100%) 50 (96.2%) ns   
 -PAH, n (%) 6 (27.3%) 4 (7.8%) 0.0570 4.4 1.1–17.6
 -Interstitial lung disease, n (%) 10 (45.5%) 16 (29.6%) ns   
 -Raynaud phenomenon, n (%) 22 (100%) 54 (100%) ns   
 -ACA pos., n (%) 8 (36.4%) 17 (31.5%) ns   
 -Scl70 pos., n (%) 9 (40.9%) 22 (40.7%) ns   
 -RNAP III pos., n (%) 2 (9.1%) 1 (1.9%) ns   
Medications
 -Iloprost 14 (63.6%) 29 (53.7%) ns   
 -Bosentan 6 (27.3%) 5 (9.3%) ns   
 -Oral vasodilators2 18 (81.8%) 32 (59.3%) ns   
Capillaroscopy pattern
 -Early, n (%) 0 (0%) 13 (24.1%) 0.0265 18.66 1.1-326.4; p = 0.0035
 -Active, n (%) 11 (50.0%) 16 (29.6%)
 -Late, n (%) 11 (50.0%) 21 (38.9%)
 -Non-SSc, n (%) 0 (0%) 2 (3.7%)
 -Not done, n (%) 0 (0%) 2 (3.7%)
  1. CI confidence interval, dcSSc diffuse limited cutaneous systemic sclerosis, ns not significant
  2. 1Baseline cohort: n = 79, 3 drop-outs
  3. 2ACE inhibitors, AT1 blockers, PDE5 inhibitors, calcium channel blockers, alpha1 antagonists
  4. 3Cut-off > 8 points
  5. 4Cut-off > 20 points
  6. 5Thickening proximal of MCP compared to other/no skin involvement
  7. 6Cut-off types, active and late